Shots:
- Genentech has reported the P-III (FENtrepid) trial data assessing fenebrutinib (QD, PO) with IV Ocrevus-matching PBO vs Ocrevus & oral fenebrutinib-matching PBO in 985 adults with PPMS
- Trial met its 1EP, showing a 12% reduction in disability progression (cCDP12) with curves separating by wk. 24 & consistent benefit across subgroups & duration. The strongest effect was on 9HPT (26% risk reduction), with post-hoc analysis showing superiority on the EDSS+9HPT composite (22% risk reduction)
- Genentech plans to submit data from all P-III trials of fenebrutinib to regulatory authorities after the readout from P-III (FENhance 1) trial in relapsing MS, expected in the H1’26
Ref: Genentech | Image: Genentech | Press Release
Related News: Genentech to Advance RNAi Therapeutics with SanegeneBio in a ~$1.7B Deal
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
